A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Inclusion Criteria:

• Medically stable based on physical examination, medical history, vital signs,electrocardiogram (ECG) at screening

• Chronic hepatitis B virus (HBV) infection with documentation at least 6 months priorto screening

• Hepatitis B e (antigen) (HBeAg)-negative on stable nucleotide analogue (NA) treatmentfor at least 24 months prior to screening

• Hepatitis B surface antigen (HBsAg) greater than (>) 100 International Units perMilliliter (IU/mL) at screening

• Body mass index (BMI) between 18.0 and 35 kilogram per meter square (kg/m^2), extremesincluded

• Highly effective contraceptive measures in place for female participants ofchildbearing potential or male participants with female partners of childbearingpotential

• Liver fibrosis stage 0-2 (Metavir) or Fibroscan less than (<) 9 Kilopascal (kPa) atscreening

Exclusion Criteria:

• Evidence of infection with hepatitis A, C, D or E virus infection or evidence of humanimmunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening

• History or evidence of clinical signs/symptoms of hepatic decompensation including butnot limited to: portal hypertension, ascites, hepatic encephalopathy, esophagealvarices or any laboratory abnormalities indicating a reduced liver function as definedin the protocol

• Evidence of liver disease of non-HBV etiology

• History or signs of cirrhosis or portal hypertension (nodules, no smooth livercontour, no normal portal vein, spleen size ≥12 cm) or signs of hepatocellularcarcinoma (HCC)

• Significant laboratory abnormalities as defined in the protocol at screening

• Participants with a history of malignancy within 5 years before screening

• Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol

• History of or current cardiac arrhythmia or history or clinical evidence ofsignificant or unstable cardiac disease

• Participants with any current or previous illness for which, in the opinion of theinvestigator and/or sponsor, participation would not be in the best interest of theparticipant

• History of or current clinically significant skin disease or drug rash

• Known allergies, hypersensitivity, or intolerance to JNJ-73763989 and JNJ-56136379 ortheir excipients or to placebo content

• Contraindications to the use of entecavir (ETV), tenofovir disoproxil fumarate (TDF),or tenofovir alafenamide (TAF) per local prescribing information

• Participants who have taken any therapies disallowed per protocol